)
Edge12 Dec 2025
Running on Clouds: The Story of On
The story of how a Swiss runner's pursuit of a new running sensation became On, aiming to be the most premium global sportswear brand worldwide.
Acumen Pharmaceuticals
Acumen Pharmaceuticals (ABOS) investor relations material
Acumen Pharmaceuticals Q3 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2025 earnings summary12 Nov, 2025
Executive summary
Advanced Phase II ALTITUDE-AD trial for sabirnetug in early Alzheimer's disease, with enrollment of 542 participants completed in March 2025 and first patients entering the open-label extension in November 2025; topline results expected in late 2026.
Entered a strategic collaboration with JCR Pharmaceuticals in July 2025 to develop Enhanced Brain Delivery (EBD) therapies for Alzheimer's, leveraging blood-brain barrier technology and including potential milestone and royalty payments.
Added Dr. George Golumbeski as Chairman, expanding the board to eight members and strengthening business development expertise.
Cash and marketable securities totaled $136.1 million as of September 30, 2025, expected to fund operations into early 2027.
Reported a net loss of $96.2 million for the nine months ended September 30, 2025, primarily driven by research and development expenses.
Financial highlights
R&D expenses were $22 million for Q3 2025, down year-over-year due to reduced CRO costs after ALTITUDE-AD trial enrollment completion; for the nine months ended September 30, 2025, R&D expenses increased 42% year-over-year to $84.4 million due to higher manufacturing, CRO, and personnel costs.
G&A expenses were $4.5 million for Q3 2025, reflecting lower legal, audit, and recruiting costs; for the nine months ended September 30, 2025, G&A expenses decreased 6% year-over-year to $14.3 million.
Net loss for Q3 2025 was $26.5 million, compared to $29.8 million in Q3 2024; net loss per share was $0.44 for Q3 2025.
Net loss per share for the nine months ended September 30, 2025, was $1.59, compared to $1.09 for the same period in 2024.
Interest income declined 46% year-over-year to $6.1 million for the nine months ended September 30, 2025.
Outlook and guidance
Topline results from the ALTITUDE-AD Phase II trial are anticipated in late 2026, with open-label extension providing additional long-term safety and efficacy data.
Decision on advancing an EBD product candidate expected in early 2026, with non-clinical data, including a non-human primate study, to inform candidate selection.
Cash and marketable securities are expected to fund operations into early 2027, but additional funding will be needed for future operations and commercialization.
Confident in operational execution and advancing next-generation Alzheimer's treatments.
EBD program: Define 'meaningful increase' for go/no-go
ALTITUDE-AD: What defines a 'clear and demonstrable effect'?
EBD program: How is anemia risk minimized with JCR?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Acumen Pharmaceuticals earnings date
Q4 202524 Mar, 2026
Acumen Pharmaceuticals
Next Acumen Pharmaceuticals earnings date
Q4 202524 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Acumen Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company primarily engaged in the discovery and development of therapies for the treatment of Alzheimer's disease. The company's most advanced candidate is ACU193, a humanized monoclonal antibody designed to target toxic soluble amyloid-beta oligomers. These amyloid-beta oligomers are associated with the neurodegeneration seen in Alzheimer’s disease patients. Acumen Pharmaceuticals was founded in 1996 and focuses on progressing its immunotherapy approach to offer potential disease-modifying treatments. The company is headquartered in Charlottesville, Virginia, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage